A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.

Start Date10 Jan 2020

Sponsor / Collaborator

Yiviva, Inc.

NCT02178644

/ CompletedPhase 1IIT

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.

Start Date01 Jul 2014

Sponsor / Collaborator

Yale University

NCT00730158

/ CompletedPhase 2IIT

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

Start Date01 Dec 2008

Sponsor / Collaborator

University of Pittsburgh

[+1]

100 Clinical Results associated with YIV-906

100 Translational Medicine associated with YIV-906

100 Patents (Medical) associated with YIV-906

Literatures (Medical) associated with YIV-906

01 Jun 2024·Journal of Gastrointestinal Oncology

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Article

Author: Liu, Shwu-Huey ; Higgins, Susan A ; Lam, Wing ; Hochster, Howard ; Zaheer, Wajih ; Cheng, Yung-Chi ; Johung, Kimberly L ; Kortmansky, Jeremy ; Verma, Nipun ; Lacy, Jill ; Stein, Stacey ; Cecchini, Michael ; Reddy, Vikram

Background:

Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether the addition of YIV-906, a novel herbal medicine proven to reduce GI toxicity associated with chemotherapy could also reduce GI side effects during standard pre-operative capecitabine and pelvic radiation therapy (RT) in the neoadjuvant setting for the treatment of locally advanced rectal cancer.

Methods:

This single arm clinical study enrolled 24 patients between Dec 23, 2014-Sep 17, 2018 at Smilow Cancer Hospital, a comprehensive cancer center at Yale New Haven Hospital. All patients were age ≥18 years, Eastern Cooperative Oncology Group 0-1 and with histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum. Median follow-up was 61.9 months. All patients received concurrent pelvic external beam RT (50.4 Gy in 28 fractions), YIV-906 (taken orally 800 mg twice daily on days 1-4 of RT each week), and oral capecitabine delivered in a neo-adjuvant fashion, followed by definitive surgery. Toxicity was assessed weekly during radiation and until acute symptoms resolved and then at 28 days, 4 months, 7 months and 10 months. Toxicities were graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results:

At the time of surgery, 4 patients (16.7%) had a complete or near-complete response. At a median follow-up of 61.9 months, the mean overall survival (OS) of our patient cohort was 74.9 months [95% confidence interval (CI): 67.3-82.5]. The estimated 5-year OS was 82.0%. We observed 0% acute grade 4 toxicities, and only two cases of acute grade 3 diarrhea (8.3%).

Conclusions:

The addition of YIV-906 to capecitabine based chemoradiation for locally advanced rectal cancer led to reduced rates of GI toxicity compared to historical controls, in particular grade 3 or greater diarrhea. These findings suggest YIV-906 should be evaluated in a randomized clinical trial to further assess potential reductions in the toxicity profile of chemoradiation for GI cancers.

01 Jan 2024·Integrative cancer therapies

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Review

Author: He, Bing ; Zhang, Wei ; He, Yanxi ; Xiong, Xia ; Qi, Xiaoyi ; Liang, Sicheng ; Wang, Xuan ; Wang, Yu ; Wu, Lili ; Deng, Mingming ; Zhao, Wenjing

Background::

Irinotecan is widely used in the treatment of various solid tumors, but the adverse effects from it, especially diarrhea, limit its use. Several clinical trials of prophylactic treatment of irinotecan-induced diarrhea (IID) have been ongoing, and some of the data are controversial. This encouraged us to conduct a meta-analysis of the effects of interventions on preventing IID.

Method::

This systematic review was conducted based on the PRISMA statement. We performed literature searches from PubMed, Web of Science, Embase, and Cochrane Library. The number registered in PROSPERO is CRD42022368633. After searching 1034 articles in the database and references, 8 studies were included in this meta-analysis.

Result::

The RR of high-grade diarrhea and all-grade diarrhea were 0.31 ( I2 = 51%, 95% CI: 0.14-0.69; P = .004) and .76 ( I2 = 65%, 95% CI: 0.62-0.93; P < .008) respectively, thus the use of intervention measures for preventing IID is effective, and the risk reduction of high-grade diarrhea was more significant. Subgroup analysis revealed that the monotherapy group (RR: 0.48, 95% CI: 0.21-1.13, I2 = 0%) and combination therapy group (RR: 0.14, 95% CI: 0.06-0.32, I2 = 0%) in the risk of high-grade diarrhea had no significant heterogeneity within the groups, and traditional herbal medicines (Kampo medicine Hangeshashin-to, PHY906 and hot ironing with Moxa Salt Packet on Tianshu and Shangjuxu) were effective preventive measures (RR:0.20, 95% CI: 0.07-0.60, I2 = 0%). The Jadad scores for traditional herbal medicines studies were 3, and the follow-up duration was only 2 to 6 weeks.

Conclusion::

This systematic review and meta-analysis suggest that preventive treatments significantly reduced the risk of high-grade and all-grade diarrhea, confirming the efficacy in the incidence and severity of IID, among which traditional herbal medicines (baicalin-containing) provided a protective effect in reducing the severity of IID. However, the traditional herbal medicines studies were of low quality. Combined irinotecan therapy can obtain better preventive effects than monotherapy of IID. These would be helpful for the prevention of IID in clinical practice.

01 May 2021·Chinese journal of natural medicines

A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan

Article

Author: Wan, Jian-Bo ; Xu, Dou-Dou ; Xu, Feng-Guo ; Hou, Xiao-Ying ; Wang, Ou ; Wang, Di ; Zhang, Zun-Jian ; Qin, Si-Yuan ; Dai, Xiao-Min ; Li, Dan-Ting ; Lv, Bo

Huang-Qin Decoction (HQD) is a classic prescription for diarrhea in Chinese medicine treatment. Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan (CPT-11) induced gastrointestinal (GI) toxicity and enhance its anticancer therapeutic efficacy. Nevertheless, which constituents in HQD are effective is still unclear so far. The study aims to screen out the key bioactive components combination from HQD that could enhance the anticancer effect of CPT-11. First, the potential bioactive constituents were obtained through system pharmacology strategy. Then the bioactivity of each constituent was investigated synthetically from the aspects of NCM460 cell migration, TNF-α release of THP-1-derived macrophage and MTT assay in HCT116 cell. The contribution of each constituent in HQD was evaluated using the bioactive index E_i, which taken the content and bioactivity into comprehensive consideration. And then, the most contributing constituents were selected out to form a key-component combination. At last, the bioefficacy of the key-component combination was validated in vitro and in vivo. As a result, a key-component combination (HB4) consisting of four compounds baicalin, baicalein, glycyrrhizic acid and wogonin was screened out. In vitro assessment indicated that HB4 could enhance the effect of CPT-11 on inhibiting cell proliferation and inducing apoptosis in HCT116. Furthermore, the in vivo study confirmed that HB4 and HQD have similar pharmacological activity and could both enhance the antitumor effect of CPT-11 in HCT116 xenograft model. Meanwhile, HB4 could also reduce the CPT-11 induced GI toxicity.

News (Medical) associated with YIV-906

13 Aug 2024

·www.drugs.com

Chinese Botanical Medicine Eases a Cancer Treatment Side Effect

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest. A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers reported recently in the Journal of Gastrointestinal Oncology . YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said. “This study is the first demonstration of YIV-906’s effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine’s potential of improving the patient’s quality of life while increasing treatment effectiveness,” said co-researcher Yung-Chi Cheng , a professor of pharmacology at Yale School of Medicine who helped develop the drug. For the four-year, phase 2 study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery. At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show. Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea. “We didn’t have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable,” senior researcher Dr. Susan Higgins , a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale. The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale new release. People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultRadiation TherapyPhase 2

05 Feb 2024

·www.globenewswire.com

Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo (CIIE) at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). “2023 marks the 30th anniversary of AstraZeneca in China. In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine. At CIIE, AstraZeneca announced plans to further globalize Chinese medicine. Our strategic partnership with Yiviva, will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine,” remarked Lily Zhu, Vice President of AstraZeneca China and Head of DCI and CSE. “Disease knows no borders. By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines. Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO of Yiviva. About Yiviva’s Platforms and Pipeline in Oncology Yiviva’s STAR (signal transduction, activity and response) drug discovery platform accelerates the identification of botanical therapeutics that influence immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity. Through STAR, Yiviva can design sophisticated multi-target drugs that map to complicated disease biology. Yiviva has discovered six first-in-class drug candidates to treat cancer and inflammatory diseases. Yiviva applies patented, mechanism-based quality control linked to biological activity to manufacture batch-to-batch consistent drug product that satisfies established regulatory requirements for complex products. Yiviva’s lead candidate drug YIV-906 is a proprietary extract of 4 medicinal plants, inspired by an 1800-year-old traditional Chinese medicine formula. YIV-906 acts as an immunomodulator in the tumor microenvironment, turning cold tumors hot and potentiating anti-tumor activity for chemotherapies, immunotherapies, cell therapies, or radiation therapies; and acts as a cytoprotector in the gastrointestinal tract, reducing non-hematological toxicities and speeding up damaged tissue recovery. Yiviva has conducted 8 early-stage clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancers), with promising data suggesting that YIV-906 could prolong survival and improve quality of life. Yiviva recently recruited its last-patient-in in a first-line, randomized, double-blinded Phase 2b study of sorafenib plus YIV-906 in the treatment of hepatocellular carcinoma patients with hepatitis B. The CALM study is a multi-regional trial in the United States, Mainland China, Hong Kong, and Taiwan and expects a data readout in 2024. Yiviva recently published preclinical data conducted at Yale University about its novel therapeutic YIV-818-A to treat prostate cancer. YIV-818-A acts through multiple mechanisms, including androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation and could help overcome drug resistance to prostate cancer and could enhance apalutamide, darolutamide, or enzalutamide efficacy. About Yiviva Yiviva is a clinical stage, platform biotechnology company developing systems biology medicines to prevent, treat, and/or cure aging-related diseases, including cancer and inflammatory diseases. The company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Greater China. Yiviva’s investors include the National Foundation for Cancer Research and the Asian Fund for Cancer Research. For further information, please visit https://yiviva.com. About AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contact:Email: hello@yiviva.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8

Phase 2Immunotherapy

30 Apr 2021

·www.globenewswire.com

Advanced Liver Cancer Drug Pipeline Prospers with an Inrush

Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies A comprehensive analysis of 50+ key companies and 50+ emerging therapies enriching the Advanced Liver Cancer Pipeline Landscape. DelveInsight’s ‘Advanced Liver Cancer Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development and growth prospects across the Advanced Liver Cancer domain. Some of the key highlights from the Advanced Liver Cancer pipeline report are: In the News Got queries? Want to know more? Request for Sample @ Advanced Liver Cancer Clinical Trial Analysis and Pipeline Insights Advanced Liver Cancer Pipeline Activity: At a Glance Reach out @ Advanced Liver Cancer Pipeline: Novel therapies and emerging technologies Advanced Liver Cancer Pipeline Agent Assessment The Advanced Liver Cancer Pipeline report lays down holistic coverage of active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets By Stage and Route of AdministrationBy Stage and Product Type For more information on emerging drugs, visit Advanced Liver Cancer Pipeline: Emerging Therapies and Trends Scope of the Report Coverage: GlobalKey Players: Siranomics, Novartis, Yiviva, Eisai, CAS Lamvac Biotech, Benhealth Biopharmaceutical, Chia Tai Tianqing Pharmaceutical, Surface Oncology, Zai Lab (Shanghai), Can-Fite Biopharma, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, SignalRX Pharmaceuticals, Carsgen Therapeutics, Shanghai Henlius Biotech, Jiangsu HengRui Medicine, Leap Therapeutics, Eureka Therapeutics, and many more.Key Advanced Liver Cancer Pipeline Therapies: STP 705, PDR001, YIV-906, H3B 6527, Plasmodium Immunotherapy, Activated CIK, AK105 Injection, SRF 388, MGD013, Namodenoson, SHR-1210, ET140203, PLM60, INC280, Donafenib, IBI308, SF1126, CAR-GPC3 T Cells, HLX10, and many more. Have a walkthrough of the report @ Advanced Liver Cancer Emerging Pipeline Key Questions Answered Need to clarify something? Get in touch @ Advanced Liver Cancer Drug Pipeline Insights Table of Contents Visit to know more of what’s covered @ Advanced Liver Cancer Emerging Therapies Other Insightful Reports Liver cancer IncidenceRead about the rising global burden of Liver Cancer. Excessive Daytime Sleepiness MarketGet a comprehensive analysis of epidemiology, pipeline therapies, and kye companies including Bioprojet Pharma/Harmony Biosciences, Axsome Therapeutics, Jazz Pharmaceuticals, BenevolentAI Bio, and many others. Bevacizumab Biosimilars InsightCoverage of about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. Pegfilgrastim Biosimilar InsightComprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape. Different Types of Alternative MedicineKnow more about the state of Alternative Medicine in Healthcare and their changing landscape. Adeno-Associated Virus (AAV) Vectors in Gene TherapyAnalysis of emerging therapies and key companies including Pfizer (previously Sangamo Biosciences), NightstaRx Ltd, a Biogen Company, MeiraGTx, Neurocrine Biosciences/ Voyager Therapeutics, Roche (previously Spark Therapeutics)/Pfizer, Sangamo Therapeutics, Freeline Therapeutics, Spark Therapeutics, Asklepios Biopharmaceutical (Actus Therapeutics), Audentes Therapeutics, Roche/Sarepta Therapeutics, Horama S.A., MeiraGTx UK II Ltd, RegenxBio, Sangamo Therapeutics, Amicus Therapeutics, Amicus Therapeutics, and several others. Angelman Syndrome MedicationsA rich analysis of emerging drug therapies and key companies such as GeneTX Biotherapeutics, LLC, Ultragenyx Pharmaceutical Inc, Hoffmann-La Roche, Ovid Therapeutics Inc., Biogen, and others involved in the Angelman Syndrome market. Get in-depth knowledge of the healthcare and pharma world through DelveInsight's Competitive Intelligence Services and Business Solutions. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

Gene TherapyBiosimilarImmunotherapy

100 Deals associated with YIV-906

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 2	United States	Yale University	15 Jun 2022
Advanced Hepatocellular Carcinoma	Phase 2	United States	Yiviva, Inc.	10 Jan 2020
Advanced Hepatocellular Carcinoma	Phase 2	China	Yiviva, Inc.	10 Jan 2020
Advanced Hepatocellular Carcinoma	Phase 2	Hong Kong	Yiviva, Inc.	10 Jan 2020
Advanced Hepatocellular Carcinoma	Phase 2	Taiwan Province	Yiviva, Inc.	10 Jan 2020
Metastatic Colorectal Carcinoma	Phase 2	United States	Kadmon Corp. LLC	01 Dec 2008
Pancreatic adenocarcinoma metastatic	Phase 2	United States	PhytoCeutica, Inc.	01 Dec 2006
Pancreatic adenocarcinoma metastatic	Phase 2	United States	Roche Pharma AG	01 Dec 2006
Unresectable Hepatocellular Carcinoma	Phase 2	United States	PhytoCeutica, Inc.	01 Oct 2003
Unresectable Hepatocellular Carcinoma	Phase 2	Taiwan Province	PhytoCeutica, Inc.	01 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04000737 (International phase II randomized placebo-controlled study, ASCO2025)	Phase 2	Advanced Hepatocellular Carcinoma First line HBV (+)	107	YIV-906 + Sorafenib	mxeclvzyug(gixswjgjmp) = improvement was also observed by the investigator qvvpikejwm (zmwjgxdxbj ) View more	Positive	30 May 2025
				Placebo
NCT00730158 (CTgov)	Phase 2	Metastatic Colorectal Carcinoma	33	Irinotecan+KD018 (Arm A - Irinotecan + KD018)	lvncgzdrsg = zltrvakorr eopcccywzt (hicltqqjqc, nxgdmkywno - inllwgckjd) View more	-	22 May 2019
				Placebo+Irinotecan (Arm B - Irinotecan + Placebo)	lvncgzdrsg = qstfsheuri eopcccywzt (hicltqqjqc, jkbbokshpr - wzpsrzgcuw) View more
NCT00411762 (CTgov)	Phase 1/2	Pancreatic adenocarcinoma metastatic \| Pancreatic Cancer	25	Capecitabine+PHY906	avrfizwxdt(hldxvaezql) = fyumhuqhdu ahcslztstc (rmiupupwbs, jivifeqafs - dyqfueneld) View more	-	27 Mar 2015
NCT04000737 (Pubmed \| Cancer Chemother Pharmacol)	Phase 2	Pancreatic Cancer Second line	25	Capecitabine + PHY906	budxmualrh(kqcejukwht) = jedihaekxv xfpauxbmuw (rxjxwdqujc ) View more	-	01 Feb 2014
ASCO2010	Phase 2	Pancreatic Cancer	25	PHY906 plus capecitabine (CAP)	ziskndxxsa(pwzaughjpi) = wgahswxqib gkesibfxsa (mtrpxunkip ) View more	-	20 May 2010
NCT04000737 (Pubmed)	Phase 1/2	Advanced Hepatocellular Carcinoma	-	PHY906	bosomfflaw(zdfhpmsknl) = sbjwwuyeqg ypyteskhkm (tcaxovholp ) View more	-	01 Oct 2009
ASCO2009	Not Applicable	Gastrointestinal Neoplasms	44	PHY906	tromsyohvl(piwysiphlj) = pdcplnqxad iiljtfqivd (lovkcsfflp )	-	20 May 2009
				CAP alone	tromsyohvl(piwysiphlj) = stvhvogvdp iiljtfqivd (lovkcsfflp )
ASCO2007	Phase 1/2	Hepatocellular Carcinoma	18	PHY906 + Capecitabine 1000 mg/m2 BID	cadgqdbtpl(rzueclqtfq) = hyethzhixj mqbnktyxpe (dpcfejqkgu ) View more	-	20 Jun 2007
				PHY906 + Capecitabine 750 mg/m2 BID	cadgqdbtpl(rzueclqtfq) = ikpfwilnng mqbnktyxpe (dpcfejqkgu ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

YIV-906

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation